Original Title: Prueba genómica para determinación de pacientes de bajo riesgo de cáncer de pulmón con broncoscopia no concluyente

Authors' objectives: To assess the safety and efficacy of the PERCEPTA® GSC test for the classification of patients at low risk of lung cancer with potentially cancerous lung nodules but inconclusive bronchoscopy findings.

Authors' results and conclusions: Applying the inclusion and exclusion criteria, the final selection process yielded seven studies, while a manual review of the references in the selected papers and a search update retrieved one and three more studies, respectively. The majority of the individual studies included were based on cohorts of patients from the AEGIS-I and AEGIS-II studies on airway epithelial gene expression in the diagnosis of lung cancer. The data from the studies included showed an advantage of using the Percepta classifier in terms of a reduction in the use of invasive procedures in patients with suspected lung cancer. Further, the information provided by Percepta was shown to significantly influence clinical decisions by helping clinicians in the identification of the most appropriate management strategy for patients. Finally, the studies that included cost-effectiveness analysis suggested that the use of genomic classifiers could be considered an efficient strategy for the diagnosis of lung cancer. Conclusions The Percepta® GSC test may be a reliable and effective tool for assessing cancer risk in patients with suspicious lung nodules in a clinical setting. Nonetheless, further data are required from high quality research to provide sufficient objective support and context for the final decision on whether to recommend the adoption of this technology.

Authors' methods: A structured literature search was performed to retrieve studies providing evidence on genomic tests for the classification of patients at low risk of lung cancer with inconclusive bronchoscopy findings, using lung neoplasms, bronchoscopy, genomic testing and risk, among other terms, as free text and controlled vocabulary, as well as the name of the specific device to be assessed: Percepta. A preliminary descriptive analysis was carried out to gather information on the characteristics of each study.

Project Status: Completed

Year Published: 2024

URL for published report: https://www.euskadi.eus/contenidos/informacion/2024_osteba_publicacion/eu_def/adjuntos/E-24-04-Prueba_cancer_pulmon_broncoscopia.pdf

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Spain

Organisation Name: Basque Office for Health Technology Assessment

Contact Address: C/ Donostia – San Sebastián, 1 (Edificio Lakua II, 4ª planta) 01010 Vitoria - Gasteiz

Contact Name: Lorea Galnares-Cordero

Contact Email: lgalnares@bioef.eus

Copyright: <p>Osteba (Basque Office for Health Technology Assessment) Health Department of the Basque Government</p>